Zomedica Corp. (ZOM)
- Previous Close
0.1301 - Open
0.1319 - Bid 0.1337 x 36900
- Ask 0.1339 x 1100
- Day's Range
0.1319 - 0.1343 - 52 Week Range
0.1200 - 0.2450 - Volume
2,538,874 - Avg. Volume
4,734,820 - Market Cap (intraday)
130.333M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
www.zomedica.comRecent News: ZOM
Performance Overview: ZOM
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZOM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZOM
Valuation Measures
Market Cap
130.33M
Enterprise Value
42.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.17
Price/Book (mrq)
0.54
Enterprise Value/Revenue
1.69
Enterprise Value/EBITDA
-1.45
Financial Highlights
Profitability and Income Statement
Profit Margin
-137.10%
Return on Assets (ttm)
-7.41%
Return on Equity (ttm)
-13.61%
Revenue (ttm)
25.19M
Net Income Avi to Common (ttm)
-34.53M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
90.5M
Total Debt/Equity (mrq)
1.14%
Levered Free Cash Flow (ttm)
-22.81M